Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship

Angela B. Mariotto, Julia H. Rowland, Lynn A.G. Ries, Steve Scoppa and Eric J. Feuer
Angela B. Mariotto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia H. Rowland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynn A.G. Ries
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Scoppa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric J. Feuer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-06-0782 Published March 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Objective: The present study was designed to estimate the number of and describe the pattern of disease among cancer survivors living with a history of multiple malignant tumors in the United States.

Methods: Incidence and follow-up data from the Surveillance, Epidemiology, and End Results program (1975-2001) were used to calculate the number of survivors with more than one malignant primary at January 1, 2002. U.S. prevalence counts were calculated by multiplying the age, sex, and race-specific prevalence proportions from the Surveillance, Epidemiology, and End Results program by the corresponding U.S. populations.

Results: We estimate that 756,467 people in the United States have been affected by cancer more than once between 1975 and 2001, representing almost 8% of the current cancer survivor population. Women whose first primary in that period was breast cancer represent 25% of survivors with multiple cancers, followed by men and women (15%) whose first primary was colorectal cancer and men (13%) whose first primary was prostate cancer.

Discussion: The findings in this report have important implications for public health practice. With individuals diagnosed with cancer living longer and the aging of the U.S. population, the number who will develop multiple malignancies is expected to increase. As a consequence, there is a growing need to promote effective cancer screening along with healthy life-styles among these at-risk populations if we are to ensure optimal physical and psychosocial well-being of these long-term cancer survivors and their families. Efforts to design and evaluate effective, efficient, and equitable approaches to surveillance for second malignancies will be critical in reducing the national burden of cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(3):566–71)

  • Descriptive, Risk Factor, and Methodological Studies
  • Second cancers
  • Epidemiology of survivorship

Introduction

In the last three decades, cancer has been transformed from a fatal disease to one in which the majority of people diagnosed with cancer receive highly effective treatments that result in either cure or long-term survivorship. The number of people in the United States living with a cancer diagnosis has more than tripled from 1970 (1), and at January 1, 2003, it is estimated to include 10.5 million individuals (2). Factors that will continue to drive the increase in the number of survivors include the aging of the baby-boom generation, longer life-expectancy, increased use of effective cancer screening, and improvements in treatment. Eighteen percent (6.3 million) of the U.S. population, ages ≥65 years, have had a cancer (3). Although most cancer survivors have ages ≥65 years, more than one third have ages of <65 years. It is known that individuals with cancer are at increased risk for subsequent tumors (4-8) and further that, the reported prevalence estimates include people diagnosed with more than one primary malignant tumor. Risk may be due to several reasons, including genetic predisposition, environmental exposure, exposure to carcinogenic cancer therapies (i.e., iatrogenic risks associated with chemotherapy, radiotherapy and/or hormonal therapy), life-style factors, such as smoking, and, perhaps most importantly, aging. Demographic trends make this last risk factor particularly salient. Given that cancer is a disease associated with aging, as the U.S. population ages and cancer survival lengthens, the growing number of survivors with multiple malignant primary tumors will become an increasingly important medical issue, particularly among the elderly.

The aim of this work is to estimate the number of and describe the pattern of disease among cancer survivors living with a history of multiple malignant tumors in the United States. Frequency of multiple primary cancers of the same sites, as well as different sites, are examined, in relation to survivors' sex, age, race, time since diagnosis, and site of first tumor. Most previous analyses of multiple tumors, including a highly cited monograph using the Connecticut Tumor Registry (4), many subsequent papers (5-8), and a recent monograph using data from the Surveillance, Epidemiology, and End Results (SEER) program (9), focus on estimating the risk and causes of developing second or later primaries among specific groups of cancer survivors. These analyses compare the risk of developing a subsequent cancer relative to the general population risk. This paper is distinguished from these prior efforts, in that here, we estimate the number of persons alive diagnosed with multiple cancers rather than the excess risk. This measure represents the current population burden of people affected by cancer more than once and serves as an estimate of the potential financial, emotional, and social effects it creates. The motivation for this effort is the increasing public and research attention being focused on survivorship research and cancer care (10). Although we hear or know of people who have had more than one diagnosis of cancer, to our knowledge, this is the first population-based estimate of the number of U.S. cancer survivors who had more than one diagnosis of cancer. Understanding and knowing the U.S. cancer survivor population with respect to all its dimensionality, as for example, the occurrence of multiple tumors, will help to inform policy makers, researchers, and clinicians on how to better allocate resources and refine research questions geared to improving cancer survivorship outcome.

Materials and Methods

This report uses incidence and follow-up data from the SEER program registries in five states (Connecticut, Hawaii, Iowa, New Mexico, and Utah) and four metropolitan areas (Atlanta, Detroit, San Francisco-Oakland, and Seattle; ref. 11). Only malignant primary cancers diagnosed between 1975 and 2001 were considered and prevalence is calculated as of January 1, 2002. Each person was classified as having (a) only one primary cancer, (b) more than one primary in the same cancer site, or (c) more than one primary in at least two different cancer sites. The list of main sites used to classify tumors as belonging to the same or different site is given in Appendix A. First site is defined as the first primary cancer reported in the 1975 to 2001 period, although an individual could have had a primary cancer before 1975. This definition is used because it permits data consistency (e.g., Seattle joined SEER in 1974 and Atlanta in 1975) and also because there is a lack of information on cancers diagnosed before 1973. SEER collects the number (but not the site or behavior) of cancers that occur before the start of the registry. Age at prevalence is categorized in ranges (0-19, 20-49, 50-59, 60-69, 70-79, and 80+ years). Prevalence statistics by site of first primary in the 1975 to 2001 period are calculated by counting the person just once for her/his first primary cancer site. Thus, if a woman was diagnosed with a cancer (site unknown) before SEER at age 46 in 1970 and later diagnosed with breast cancer at age of 61 years in 1985 and subsequently developed colorectal cancer at age of 71 years in 1995, she would be classified as follows: breast (first primary), more than one primary mixed site, ages 70 to 79 years (at prevalence). Because all statistics are based on 1975 to 2001 data, her first cancer is ignored in the statistics. For each individual lost to follow-up, his or her probability of being alive at the prevalence time is estimated from an appropriate (age and year at diagnosis, race, sex, and first primary site) survival function, conditional on the time lost to follow-up (12). U.S. prevalence counts are calculated by multiplying the SEER age, sex, and race-specific prevalence proportions (p̂race,sex,age) by the corresponding January 1, 2002 U.S. population, (Nrace,sex,age). Combined U.S. cancer prevalence counts for all races are estimated by summing the counts for Whites/unknown, Blacks, and other races as follows:Math

Similarly, combined U.S. cancer prevalence counts for all ages are estimated by summing the counts for all ages and so on. To adjust for age differences in different subgroups (sex and/or race), the age-adjusted prevalence percentages are calculated by averaging age-specific prevalence percentages using as weights the 2000 U.S. standard population. Variance for the U.S. prevalence estimates are calculated asMath

However, they represent a lower bound because they only include the Poisson variability of SEER prevalence estimates (13) and not the variability in extrapolating SEER rates to the U.S. population.

The SEER rules (14) used to determine if the cancer is a later primary cancer consider the cancer site of origin, date of diagnosis, histology, behavior (i.e., in situ versus malignant), and laterality of paired organs. In general terms, tumors in different sites of different histologic types are considered separate primaries. Multiple lesions of different histologic types occurring at the same site are considered separate primaries regardless or whether they occur simultaneously or at different times. Further, a new cancer with the same histology and same site as an earlier one is considered to be the same primary cancer if diagnosed within 2 months or a separate primary tumor if diagnosed after 2 months, unless stated in the medical record to be a recurrent or metastatic disease. If an organ is paired, each member of the pair, generally, is considered a separate site. The SEER rules include several exceptions to the standard rules that pertain to histology, laterality, and dates of diagnosis. Exceptions worth mentioning are multiple invasive adenocarcinomas of the prostate and multiple invasive bladder cancers with histologic codes 8120 to 8130, reported as a single primary with the date of the first invasive lesion. A different set of rules are used to determine multiple primaries of the lymphatic and hematopoietic diseases. Metastatic and/or recurrent tumors, which are tumors that contain cells that are like those in the original (primary) tumor, are excluded from the SEER definition and not reported.

Results

We estimate that of the estimated 9.6 million survivors diagnosed between 1975 and 2001, 7.9% were diagnosed with more than one primary malignant tumor. This represents 756,467 people living with a history of multiple primary cancers (Table 1 ). Of these individuals, 74% had two or more cancers of different primary sites, whereas 26% were diagnosed with two or more tumors of the same site. Although it seems there is a higher prevalence of multiple tumors among White males and females compared with Blacks, for males this difference is due to an older White population compared with the Black male population. After adjusting to the 2000 U.S. standard population, the differences in cancer prevalence among White and Black males disappear but not for women. Cancer prevalence for White females is higher than for Black females.

View this table:
  • View inline
  • View popup
Table 1.

Estimated number of cancer survivors in the United States alive at January 1, 2002, who had at least one primary in the last 27 yrs, by number of malignant tumors, race, sex, and type of multiple tumors

Table 2 shows the number of cancer survivors who had at least one primary in the last 27 years, by site of first primary, type of multiple primary, and age at prevalence date. Female breast is by far the site with the highest percentage of individuals with more than one primary of the same site (105,614), followed by colorectal cancer (36,082) and melanoma (15,601). The highest prevalence of multiple tumors, in order, occurs respectively when the first cancer is prostate cancer (94,477), female breast cancer (87,093), colorectal cancer (78,923), and urinary bladder (51,856). It is noted that people, ages ≥50 years, at January 1, 2002, who may have been diagnosed with leukemia during childhood (at ≤19 years), would have received this diagnosis before 1975 and, thus, before SEER data collection. This accounts for the zeros in the cells of Table 2 for people, ages ≥50 years, diagnosed with leukemia as children or adolescents. The cancer sites which show the highest prevalence of multiple tumors among its survivors (ages at diagnosis, >19 years), in order, are leukemia (14%), followed by urinary bladder (11.9%), kidney and renal pelvis (11.3%), and colorectal cancer (11.3%).

View this table:
  • View inline
  • View popup
Table 2.

Estimated number of cancer survivors in the United States alive at January 1, 2002, who had at least one primary in the last 27 yrs, by site of first primary, type of multiple tumors, and age at prevalence date

Table 3 shows sites of second or later primaries in percentages by site of first primary among survivors with two or more primary cancers. Among males, the most frequent site for a second or later primary is prostate, followed by colon and rectum, urinary bladder, and lung and bronchus. For female survivors, the most frequent second or later sites are breast, female genital system, colon and rectum, and lung and bronchus. For both male and female survivors, there is higher frequency of having later tumors of the same site as the first tumor, as well as tumors in sites which are the most frequent sites of cancer, such as prostate cancer and breast cancer among males and females, respectively. In addition, there is a correlation between multiple cancers across some of the sites, as for example, bladder, kidney and renal pelvis on the one hand, and oral cavity, pharynx, and lung and bronchus for males on the other hand. The latter representing cancer sites associated to a common risk factor, such as smoking (9).

View this table:
  • View inline
  • View popup
Table 3.

Sites of second or later tumors among survivors diagnosed with more than one primary tumor in SEER between 1975 and 2001 by sex and site of primary tumor

Whereas cancers of the same site seem most frequently within 5 years of the original diagnosis for men and women combined, the most likely time for a second or later tumor of a different site to occur is between 5 and 10 years from the diagnosis of the first primary tumor (Table 4 ).

View this table:
  • View inline
  • View popup
Table 4.

Estimated number of cancer survivors in the United States alive at January 1, 2002, who had at least one primary in the last 27 yrs, by time because diagnosis of their first tumor, type of multiple tumors, and sex

Discussion

Advances in early detection, treatment, and supportive care have led to a record number of cancer survivors or individuals living with a cancer history in the United States. These survivors are teaching us, however, that, for some, cure comes with a significant cost. With the increased survival of cancer patients, the number of people who will go on to have additional tumors is also rising. In the majority of cases, this will be due to simply living longer to ages at which the risk of developing cancer is higher. In 2002, from a total of 125,623 tumors reported to the SEER-9 areas, 20,469 (16%) represented second or later primary cancers. One important area of research has been to monitor and identify the risk factors for development of multiple tumors as a complication of cancer therapy, including second cancers induced by radiotherapy or chemotherapeutic and hormonal agents (7, 8, 15-18). Investigators also have used SEER data to explore hypotheses on the environmental, genetic, life-style, and other causes of increased second cancer risk (4, 9, 19).

To our knowledge, this is the first time that the number of people living with more than one primary cancer in the United States is estimated. We estimate that there are 756,467 people diagnosed with more than one primary cancer in the United States. White women experience the highest burden of both multiple tumors, as well as single tumors. Breast, colon and rectum, and prostate are the sites with the highest prevalence of multiple tumors. We estimate that 192,708, 115,005, and 94,606 people with a first diagnosis of female breast, colorectal, and prostate cancer between 1975 and 2001, respectively, have a second or later primary cancer.

The estimates of the prevalence of multiple tumors provided here are subject to some limitations. First, these estimates reflect cancers diagnosed between 1975 and 2001 and not lifetime or complete prevalence, which represents all previous diagnosis. Lifetime prevalence can be calculated for first primaries only by using a statistical method that estimates the proportion of tumors diagnosed before years with data (20). However, survivors diagnosed between 1975 and 2001 represent a large proportion (95%) of the 10.1 million lifetime cancer survivors at January 1, 2002 (21). Using a more recent database, the lifetime cancer survivors at January 1, 2003, is estimated to be 10.5 million (2). Second, the estimates reflect the current SEER coding rules for multiple primaries, which have been used for over 25 years and are consistent with prior publications (5-9). The current rules may overcount multiple tumors, because some of the tumors with the same histology, diagnosed more than 2 months apart from a previous one and coded as later primary, actually, may represent a recurrence. The current rules have been revised. And beginning in 2007, site-specific rules with different time intervals to distinguish between multiple primaries and recurrences will be used (22). The 2007 rules specify site-specific cut points to distinguish between recurrence and primary tumors. For breast, the cut point is 5 years, whereas, for colon, it is 1 year. The effect of the different cut points for colon and breast are small but not negligible. For example, of the 20,651 second breast tumors reported in SEER from 1975 to 2001, only 357 (1.7%) had the same histology and were diagnosed within 5 years and in the same breast as the first breast cancer. Of the 6784 second colon tumors reported, 358 (4.0%) had the same histology and were diagnosed between 2 months and 1 year from the first colon cancer. The international coding rules (23) are less flexible and report only the first tumor ever. Third, the projection of prevalence proportions from SEER to the U.S. population account for differences in age and race distribution in the United States and SEER but not other factors, such as socio-economic status. Fourth, SEs are based on SEs from the SEER prevalent proportions. They are an underestimate because they do not account for random variation in extrapolating SEER proportions to the United States. The error in the SEER proportion estimates might be much smaller than the error in sampling from the United States.

A final caveat to interpretation of these findings is that a higher prevalence of multiple tumors might be related to a higher overall survival, both high cancer specific survival as well as greater life expectancy (i.e., lower all cause mortality) or higher risk of developing second or later primaries. Thus, the observation that prevalence of multiple tumors was highest among the White female population compared with the Black female population might be explained by higher overall survival for White women, as well as a higher screening rate among the White population (24), which may lead to more diagnoses and longer survival if these cancers are diagnosed at early stages.

With the exception of breast cancer, it is not surprising that the prevalence of multiple cancers where the sites are different is higher than the prevalence of multiple cancers where the sites are the same (Table 2). This is true because although the risk of developing a second cancer of the same site is sometimes substantially elevated above the risk in the general population, the combined likelihood of developing one of the many other types of cancer usually exceeds that of a second cancer of the same site. Female breast cancer is an exception, probably due to the high risk of developing a second breast cancer. The prevalence of multiple cancers of the same site for men diagnosed with prostate cancer is very small because only the first invasive adenocarcinoma of the prostate is counted and recorded in SEER even if a second one is diagnosed 2 or more months after the first one.

In this report, the cancer-survivor population is qualified in terms of being affected more than once by cancer. In terms of quantifying other segments of the cancer survivor population, research is being done to develop methods that estimate the proportions of survivors who will be cured from their cancer (cure prevalence; ref. 25), remain in active therapy (26), are living with a chronic illness or disability, or who will eventually die of their cancer by recurrences. Characterizing the cancer-survivor population is important to better target care and health promotion.

The findings in this report have important implications for public health practice. There is a growing need to promote health and ensure the social, psychological, and economic well-being of long-term cancer survivors and their families (10). People with multiple tumors represent a segment of the cancer survivor population affected more than once by cancer. Despite this, little has been written about the experience of or health-related quality of life outcomes for this vulnerable subpopulation (27), and more research is needed. Attention in particular to the effect of survivors' health behaviors and medical follow-up care on their overall morbidity and mortality is a growing area of clinical and research focus (28-30). Another area in which more information is needed is treatment of second and later cancers, because treatment for the first cancer might limit what can be given when a new cancer is diagnosed. As we learn more about who is at risk for a second or multiple malignancies, it is clear that survivors and their health care providers will need to work in partnership to reduce risk and enhance both survival and the survivorship experience.

Appendix A. List of the main sites used to classify cancers occurring at the same or different sites

Oral cavity and pharynx, esophagus, stomach, small intestine, colon and rectum, anus/anal canal/anorectum, liver and intrahepatic bile duct, gallbladder, other biliary, pancreas, retroperitoneum, peritoneum/omentum/mesentery, other digestive organs, nose/nasal cavity/middle ear, larynx, lung and bronchus, pleura, trachea/mediastinum/other respiratory organs, bones and joints, soft tissue including heart, melanoma of the skin, other nonepithelial skin, breast, female genital system, prostate, testis, penis, other male genital organs, urinary bladder, kidney and renal pelvis, ureter, other urinary organs, eye and orbit, brain and other nervous system, thyroid, other endocrine including thymus, Hodgkin lymphoma, non-Hodgkin lymphoma, myeloma, lymphocytic leukemia, myeloid and monocytic leukemia, other leukemia, mesothelioma, kaposi sarcoma, and miscellaneous.

Footnotes

    • Accepted December 22, 2006.
    • Received September 15, 2006.
    • Revision received December 6, 2006.

References

  1. ↵
    CDC. Cancer Survivorship-United States, 1971-2001. MMWR 2004;53:526–9.
    OpenUrlPubMed
  2. ↵
    Ries L, Harkins D, Krapcho M, et al., editors. 2006. SEER Cancer Statistics Review, 1975-2003. National Cancer Institute. (http://seer.cancer.gov/csr/1975_2003).
  3. ↵
    Estimated United States Prevalence. National Cancer Institute, Division of Cancer (http://cancercontrol.cancer.gov/ocs/prevalence/).
  4. ↵
    Multiple primary cancers in Connecticut and Denmark. Natl Cancer Inst Monogr 1985;68:1–437.
    OpenUrlPubMed
  5. ↵
    Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484–94.
    OpenUrlAbstract/FREE Full Text
  6. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354–65.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Travis LB, Gilbert E. Lung cancer after Hodgkin lymphoma: the roles of chemotherapy, radiotherapy and tobacco use. Radiat Res 2005;163:695–6.
    OpenUrlPubMed
  8. ↵
    Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428–37.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Curtis R, Freedman D, Ron E, et al. New malignancies among cancer survivors: SEER cancer registries, 1973-2000. NIH Publication No. 05-5302. Bethesda, MD 2006.
  10. ↵
    Hewitt ME, Greenfield S, Stovall EE. From cancer patient to cancer survivor: lost in transition. Committee on Cancer Survivorship: Improving Care and Quality of Life. Institute of Medicine and National Research Council of the National Academies 2005.
  11. ↵
    Surveillance, Epidemiology, and End Results (SEER) Program - SEER 9 Registries, Nov 2004 Submission (1973-2002). National Cancer Institute, released April 2005, based on the November 2004 submission. (www.seer.cancer.gov).
  12. ↵
    Feldman AR, Kessler L, Myers MH, Naughton MD. The prevalence of cancer: estimates based on the Connecticut Tumor Registry. N Engl J Med 1986;315:1394–7.
    OpenUrlPubMed
  13. ↵
    Clegg LX, Gail MH, Feuer EJ. Estimating the variance of disease-prevalence estimates from population-based registries. Biometrics 2002;58:684–8.
    OpenUrlPubMed
  14. ↵
    SEER Program Coding and Staging Manual 2004 (http://seer.cancer.gov/manuals/SPM2004.pdf), pages 7–18. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program.
  15. ↵
    Rubino C, de Vathaire F, Diallo I, Shamsaldin A, Le MG. Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 2000;61:183–95.
    OpenUrlCrossRefPubMed
  16. Parker RG, Enstrom JE. Second primary cancers of the head and neck following treatment of initial primary head and neck cancers. Int J Radiat Oncol Biol Phys 1988;14:561–4.
    OpenUrlPubMed
  17. Boice JD, Jr., Day NE, Andersen A, et al. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst 1985;74:955–75.
    OpenUrlPubMed
  18. ↵
    Travis LB. Therapy-associated solid tumors. Acta Oncol 2002;41:323–33.
    OpenUrlCrossRefPubMed
  19. ↵
    Bernstein JL. Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res 2004;6:R199–214.
    OpenUrlCrossRefPubMed
  20. ↵
    Capocaccia R, De Angelis R. Estimating the completeness of prevalence based on cancer registry data. Stat Med 1997;16:425–40.
    OpenUrlCrossRefPubMed
  21. ↵
    SEER Cancer Statistics Review, 1975-2002. Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, et al., editors. 2005. National Cancer Institute. (http://seer.cancer.gov/csr/1975_2002).
  22. ↵
    2007 Multiple Primary and Histology Coding Rules (revised 11/29/2006) (http://seer.cancer.gov/tools/mphrules/mphrules_manual_01012007.pdf). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program.
  23. ↵
    International Rules for Multiple Primary Cancers. Internal Report No. 2004/02. (http://www.iacr.com.fr/MPrules_July2004.pdf) International Agency for Research on Cancer. World Health Organization, IARC, Lyon 2004.
  24. ↵
    Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003;97:1528–40.
    OpenUrlCrossRefPubMed
  25. ↵
    Gatta G, Capocaccia R, Berrino F, Ruzza MR, Contiero P, The EUROPREVAL Working Group. Colon cancer prevalence and estimation of differing care needs of colon cancer patients. Ann Oncol 2004;15:1136–42.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Mariotto A, Warren JL, Knopf KB, Feuer EJ. The prevalence of patients with colorectal carcinoma under care in the U.S. Cancer 2003;98:1253–61.
    OpenUrlPubMed
  27. ↵
    Oh S, Heflin L, Meyerowitz BE, Desmond KA, Rowland JH, Ganz PA. Quality of life of breast cancer survivors after a recurrence: a follow-up study. Breast Cancer Res Treat 2004;87:45–57.
    OpenUrlCrossRefPubMed
  28. ↵
    Ganz PA. A teachable moment for oncologists: cancer survivors, 10 million strong and growing! J Clin Oncol 2005;23:5458–60.
    OpenUrlFREE Full Text
  29. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005;23:5814–30.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Bellizzi KM, Rowland JH, Jeffery DD, McNeel T. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol 2005;23:8884–93.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 16 (3)
March 2007
Volume 16, Issue 3
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship
Angela B. Mariotto, Julia H. Rowland, Lynn A.G. Ries, Steve Scoppa and Eric J. Feuer
Cancer Epidemiol Biomarkers Prev March 1 2007 (16) (3) 566-571; DOI: 10.1158/1055-9965.EPI-06-0782

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship
Angela B. Mariotto, Julia H. Rowland, Lynn A.G. Ries, Steve Scoppa and Eric J. Feuer
Cancer Epidemiol Biomarkers Prev March 1 2007 (16) (3) 566-571; DOI: 10.1158/1055-9965.EPI-06-0782
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Appendix A. List of the main sites used to classify cancers occurring at the same or different sites
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement